UNSPSC 51351505: Ethisterone

This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P201BVY1MJ, chemically known as 17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- but generally known as ethisterone, which bears US NIH Compound Identifier 3288. European Medicines Agency schedules Ethisterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07279MIG.

UNSPSC 51351505 Ethisterone is a Commodity code capturing hormonal pharmaceutical products in state and local procurement. The recent activity under this code reflects broader demand for generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing vehicles, with state and local health systems, correctional facilities, and social-service agencies procuring through established wholesaler networks and generic-equivalent sourcing agreements rather than brand-name or single-source products. Issuing bodies soliciting under the code include state health and human-services departments and multistate cooperative purchasing alliances that aggregate demand across participating state and local facilities.

The geographic footprint is concentrated in the Upper Midwest and Pacific Northwest, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a recent RFP posted January 20, 2026, due March 26, 2026, that covers participating state and local government facilities in Minnesota and Oregon. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, is soliciting manufacturers to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with pricing effective July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify compliance with cGMP and the Drug Supply Chain Security Act, and agree to a 3 percent administrative fee. Evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria covering fixed pricing (10 percent), administrative data-format compliance (5 percent), EDI capability (5 percent), and pricing-structure flexibility (5 percent). Insurance requirements include $5 million commercial general liability and $2 million each for network security and professional liability. The contract term is two years for new responders with optional extensions, or alignment with existing agreements through June 30, 2028 for incumbents.